ProCE Banner Activity

Phase I Trial of Sutimlimab to Inhibit Classical Complement Pathway in Patients With Multi-Refractory Chronic Immune Thrombocytopenia

Slideset Download
Conference Coverage
Preliminary data showed that sutimlimab resulted in rapid and durable increase in platelet count in patients with multirefractory chronic ITP.

Released: December 18, 2019

Expiration: December 16, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company